InvestorsObserver
×
News Home

Is Atara Biotherapeutics Inc (ATRA) a Winner in the Biotechnology Industry?

Monday, November 27, 2023 09:46 AM | InvestorsObserver Analysts

Mentioned in this article

Is Atara Biotherapeutics Inc (ATRA) a Winner in the Biotechnology Industry?

Atara Biotherapeutics Inc (ATRA) is near the middle in its industry group according to InvestorsObserver. ATRA gets an overall rating of 38. That means it scores higher than 38 percent of stocks. Atara Biotherapeutics Inc gets a 37 rank in the Biotechnology industry. Biotechnology is number 53 out of 148 industries.

Overall Score - 38
ATRA has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on ATRA!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Atara Biotherapeutics Inc Stock Today?

Atara Biotherapeutics Inc (ATRA) stock is trading at $0.62 as of 9:34 AM on Monday, Nov 27, a drop of -$0.03, or -4.34% from the previous closing price of $0.65. The stock has traded between $0.62 and $0.69 so far today. Volume today is low. So far 207,237 shares have traded compared to average volume of 6,889,238 shares. Click Here to get the full Stock Report for Atara Biotherapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App